Dr Naclerio will be responsible for all corporate and business development activities, including licensing, strategic planning and acquisitions.
Before joining Illumina, Dr Naclerio served as co-founder and executive chairman of Quanterix, focusing on high-value clinical diagnostics measuring rare serum proteins. He had raised $15m in venture financing to launch the company, and invested in and raised financing for several other biotech and diagnostics companies, including Boreal Genomics, O-Link Bioscience and Fluxion Bioscience.
Dr Naclerio had previously served as executive chairman of True Materials, a particle array technology company, and president and CEO of ParAllele BioScience, a provider of solutions for large-scale genetics research, both of which were later sold to Affymetrix.
Mr Flatley said: “Nick has a long and distinguished track record building successful businesses and commercializing promising scientific and technological innovations in the diagnostics, biotech and other high-tech areas. He brings to Illumina a unique combination of strategic perspective, business leadership and investment acumen that will be instrumental to achieving our growth objectives in life sciences, molecular diagnostics and consumer genomics.”
